GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (FRA:AVU0) » Definitions » Net Intangibles Purchase And Sale

Adverum Biotechnologies (FRA:AVU0) Net Intangibles Purchase And Sale : €0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Net Intangibles Purchase And Sale?

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Adverum Biotechnologies's net Intangibles purchase and sale for the three months ended in Sep. 2024 was €0.00 Mil. Its net Intangibles purchase and sale for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Adverum Biotechnologies Net Intangibles Purchase And Sale Historical Data

The historical data trend for Adverum Biotechnologies's Net Intangibles Purchase And Sale can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Net Intangibles Purchase And Sale Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Intangibles Purchase And Sale
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adverum Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Intangibles Purchase And Sale Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adverum Biotechnologies Net Intangibles Purchase And Sale Calculation

Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Net Intangibles Purchase And Sale for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adverum Biotechnologies Net Intangibles Purchase And Sale Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Net Intangibles Purchase And Sale provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (FRA:AVU0) » Definitions » Net Intangibles Purchase And Sale
Comparable Companies
NKTR HRTX CUE VERU MIRO HOWL VICP RLMD ALDX CMRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ADVM:USA 0HA3:UK
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Website
https://www.adverum.com
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies Headlines

No Headlines